12/3/2023 0 Comments Directions to benchmark therapy![]() ![]() seamless transfer of materials, information, and work products across research groups to avoid delays.Potential process improvements include the following: This space is thus highly amenable to process redesign that may help reduce the time to the clinic without taking undue risk or compromising insight generation. Compared with early discovery stages, in this stage, research groups and their work-for example, in animal toxicology biomarkers chemistry, manufacturing, and control (CMC) discovery sciences drug metabolism and pharmacokinetics protein and cell engineering and regulatory-are highly cross-functional and less exploratory. The space from candidate nomination to investigational new drug presents a unique opportunity for accelerated drug development. We use the journey of an asset from investigational new drug to optimized portfolio resource to illustrate how the five pillars can accelerate drug development. agile ways of working, with a working model optimized for speed and decision making across the portfolio.advanced analytics (including predictive modeling), informed through internal and external data sources, that improves decision-making quality and speed.digital and technology enablement that allows automation of highly repetitive processes alongside generation of new insights and data.process redesign, both cross-functionally and within R&D groups, that improves speed of development and builds on research insights.patient- and healthcare-professional-centered design thinking, incorporated end-to-end from program and trial design to trial execution, approval, and launch. ![]() Five pillars form the basis of development excellence: Reimagining R&D demands transformation of the traditional approach to drug development to allow medicines to reach patients faster, reduce development costs, and improve insights and decision making. To transform drug development, this acceleration can be combined with improved quality and compliance, enhanced patient and healthcare-professional experience, better insights and decision making, and a reduction in development costs of up to 25 percent. In our estimation, it should be possible to bring medicines to the market 500 days faster, which would create a competitive advantage within increasingly crowded asset classes and bring much-needed therapies to patients sooner. While there is no silver bullet, drug developers can make a concerted effort to apply and integrate multiple innovations that can transform development. To make this a reality, holistic transformation is necessary. ![]() We believe the time is right for a true step change in drug development. Hansen, “Innovation in the pharmaceutical industry: New estimates of R&D costs,” Journal of Health Economics, May 2016, Volume 47, pp. Collectively, the top 20 pharmaceutical companies spend approximately $60 billion on drug development each year, and the estimated average cost of bringing a drug to market (including drug failures) is now $2.6 billion-a 140 percent increase in the past ten years. Still, drug-development costs and timelines continue to rise, and the likelihood of success continues to fall. Our understanding of biology is expanding enormously alongside increased identification of novel targets and their associated modalities. If you get 'laid off', don't expect to get called back to your job: they are just as likely to hire someone else into your position and not bother to tell you.We are living in a time of enormous scientific innovation and promise for improved human health. Don't look for any kind of annual gift or show of appreciation (like at Christmas). Don't get your hopes up about getting more PTO after a certain number of years of employment, b/c they will change the rules before you get to the 'benchmark' (pardon the pun). ![]() Don't bother accumulating PTO b/c they will take it away from you if/when you give your notice, even though it is an employee benefit that you earn. When I was confronted with problems and asked for help, no one ever had any constructive or specific feedback-I was basically told to do a better job. We could go for months without ever seeing a regional manager. I only ever heard anything if I made a mistake or if productivity wasn't met. In my years working for them as a manager, I never one time had a performance evaluation. Whereas their standards are not as rigorous as other companies, whether or not you meet them is the ONLY measure of your worth as an employee. Employees are essentially numbers who need to meet productivity standards. Benchmark started out strong as a company but quickly became like every other contract company out there. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |